50/50 triangle, but still below the 200 (bearish)looks like a picture-perfect triangle. Wait for confirmation and good luck.
0%
0%
0%
0%
0%
−3.00USD
−39.696MUSD
1.414MUSD
24.756M
About Abeona Therapeutics Inc.
Sector
CEO
Vishwas Seshadri
Headquarters
Cleveland
Website
Employees
57
Founded
1974
ISIN
US00289Y2063
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
ABEO LongAbeona Therapeutics Inc is a leading clinical-stage biopharmaceutical company. The Company develops novel gene therapies for life-threatening rare diseases. I guess the stock can surge at least to $4.94.
My trade levels:
Entry: $3.92
Take profit: $4.94
Stop loss: $3.59
Risk/reward: 3.09
Abeona Therapeutics Inc.** risky investment opportunity, $200m market capital **
Happy with the risk?
On the above 10-day chart price action has corrected a massive 95% from a high of $20 in early 2018. A number of reasons now exist to be bullish. Why?
1) Bullish divergences. Since the ‘great buy’ signal price action h
ABEO | Bullish All Year | LongAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa
Watch this one!Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa
$ABEO Next Target PTs .60-1 and higher Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated
ABEOLooking at the gap around $1.10 for a possible position.
For my educational purpose, not to be used as financial advice.
mid term +25,000% (love this one)Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
